VIPoma natural history, complications and prognosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Natural History== | ==Natural History== | ||
*If left untreated, patients with VIPoma may progress to develop | *If left untreated, patients with VIPoma may progress to develop watery [[diarrhea]], [[abdominal pain]], [[bloating]], [[nausea]], [[vomiting]], [[skin rash]], [[backache]], [[flushing]], and [[lethargy]].<ref name="NatanziAmini2009">{{cite journal|last1=Natanzi|first1=Naveed|last2=Amini|first2=Mazyar|last3=Yamini|first3=David|last4=Nielsen|first4=Shawn|last5=Ram|first5=Ramin|title=Vasoactive Intestinal Peptide Tumor|journal=Scholarly Research Exchange|volume=2009|year=2009|pages=1–7|issn=1687-8299|doi=10.3814/2009/938325}}</ref> | ||
*VIpoma have a very slow growth rate compared to most malignant tumors. | *VIpoma have a very slow growth rate compared to most malignant tumors. | ||
Revision as of 18:05, 27 October 2015
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of VIPoma natural history, complications and prognosis |
|
VIPoma natural history, complications and prognosis in the news |
|
Blogs on VIPoma natural history, complications and prognosis |
|
Risk calculators and risk factors for VIPoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Natural History
- If left untreated, patients with VIPoma may progress to develop watery diarrhea, abdominal pain, bloating, nausea, vomiting, skin rash, backache, flushing, and lethargy.[1]
- VIpoma have a very slow growth rate compared to most malignant tumors.
Complications
- Metastasis
- Cardiac arrest from low blood potassium level
- Dehydration
Prognosis
- Surgery can usually cure VIPomas. However, in one-third to one-half of patients, the tumor has spread by the time of diagnosis and cannot be cured.
- VIPoma is associated with a 5 year survival rate of 20% and 3 year survival rate of 40%.[2]
References
- ↑ Natanzi, Naveed; Amini, Mazyar; Yamini, David; Nielsen, Shawn; Ram, Ramin (2009). "Vasoactive Intestinal Peptide Tumor". Scholarly Research Exchange. 2009: 1–7. doi:10.3814/2009/938325. ISSN 1687-8299.
- ↑ Smith, Stephen L.; Branton, Susan A.; Avino, Anthony J.; Martin, J.Kirk; Klingler, Paul J.; Thompson, Geoffrey B.; Grant, Clive S.; van Heerden, Jon A. (1998). "Vasoactive intestinal polypeptide secreting islet cell tumors: A 15-year experience and review of the literature". Surgery. 124 (6): 1050–1055. doi:10.1067/msy.1998.92005. ISSN 0039-6060.